Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy

Public Health Genomics

Volumn 19, Issue 6, 2017, Pages 352-363

  Vozikis, Athanassios ^a   Cooper, David N ^b   Mitropoulou, Christina ^c,d   Kambouris, Manousos E ^c   Brand, Angela ^e   Dolzan, Vita ^f   Fortina, Paolo ^g   Innocenti, Federico ^h   Lee, Ming Ta Michael ⁱ   Leyens, Lada ^e   Macek, Milan ^j   Al Mulla, Fahd ^k   Prainsack, Barbara ^l   Squassina, Alessio ^m   Taruscio, Domenica ⁿ   Van Schaik, Ron H ^d   Vayena, Effy ^o   Williams, Marc S ⁱ   Patrinos, George P ^p  

^a UNIVERSITY OF PIRAEUS   (Greece)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Golden Helix Institute of Biomedical Research   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF LJUBLJANA   (Slovenia)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h UNC Hamner Institute for Drug Safety Sciences   (United States)

ⁱ GEISINGER HEALTH SYSTEM   (United States)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^k KUWAIT UNIVERSITY   (Kuwait)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF CAGLIARI   (Italy)

ⁿ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^o UNIVERSITY OF ZURICH   (Switzerland)

^p UNIVERSITY OF PATRAS   (Greece)

more..

Author keywords

Genomic medicine; Genomics education; Health economics; Pharmacogenomics; Policy; Public health genomics; Reimbursement; Whole genome sequencing

Indexed keywords

ARTICLE; CAPITAL; COST EFFECTIVENESS ANALYSIS; EUROPE; FUNDING; GENETIC SCREENING; GENOMIC MEDICINE; GENOMICS; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; INVESTMENT; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; COST; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PUBLIC POLICY; STATISTICS AND NUMERICAL DATA;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; GENETIC TESTING; GENOMICS; HUMANS; PUBLIC POLICY; REIMBURSEMENT MECHANISMS;

EID: 84989257383     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000449152     Document Type: Article

References (43)

1. Personalized Medicine Coalition (PMC): The Case for Personalized Medicine, ed 4. Washington, Personalized Medicine Coalition, 2014.
2. Crawford JM, Aspinall MG: The business value and cost-effectiveness of genomic medicine. Pers Med 2012; 9: 265-286.
3. Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, Ma P: The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov 2009; 8: 279-286.
4. Mitropoulou C, Mai Y, van Schaik RH, Vozikis A, Patrinos GP: Stakeholder analysis in pharmacogenomics and genomic medicine in Greece. Public Health Genomics 2014; 17: 280-286.
5. Mai Y, Koromila T, Sagia A, Cooper DN, Vlachopoulos G, Lagoumintzis G, Kollia P, Poulas K, Stathakopoulos V, Patrinos GP: A critical view of the general public's awareness and physicians' opinion of the trends and potential pitfalls of genomic testing in Greece. Pers Med 2011; 8: 551-561.
6. Mai Y, Mitropoulou C, Papadopoulou XE, Vozikis A, Cooper DN, van Schaik RH, Patrinos GP: Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Pers Med 2014; 11: 15-26.
7. Mette L, Mitropoulos K, Vozikis A, Patrinos G: Pharmacogenomics and public health: implementing 'populationalized' medicine. Pharmacogenomics 2012; 13: 803-813.
8. Prainsack B: Personhood and solidarity: what kind of personalized medicine do we want? Pers Med 2014; 7: 651-657.
9. Williams MS: The public health genomics translation gap: what we don't have and why it matters. Public Health Genomics 2012; 15: 132-138.
10. Williams MS: The genetic future: can genomics deliver on the promise of improved outcomes and reduced costs? Background and recommendations for health insurers. Dis Manag Health Outcomes 2003; 11: 277-290.
11. Williams MS: Insurance coverage for pharmacogenomic testing. Pers Med 2007; 4: 479-487.
12. The Office of Inspector General (OIG): Memorandum Report: Coverage and Payment for Genetic Laboratory Tests, Department of Health and Human Services (DHHS). OEI-07-11-00011. Washington, The Office of Inspector General, 2012.
13. The Office of Inspector General (OIG): Payments for Laboratory Tests: Comparing Medicare, State Medicaid, and Federal Employees Health Benefits Programs, Department of Health and Human Services (DHHS). OEI-07-11-00010. Washington, The Office of Inspector General, 2013.
14. Merchant M: Pricing and Reimbursement Strategies for Diagnostics: Overcoming Reimbursement Issues and Navigating the Regulatory Environment. London, Business Insights, 2010.
15. Department of Health and Human Services (DHHS): Coverage and Reimbursement of Genetic Tests and Services: Report of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS). Washington, Department of Health and Human Services, 2006.
16. National Institutes of Health: Reimbursement Models to Promote Evidence Generation and Innovation for Genomic Tests, Workshop Summary. Bethesda, National Institutes of Health, 2012.
17. Britnell M: In Search of the Perfect Health System. Basingstoke, Palgrave Macmillan, 2015.
18. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, Askaa J, Larcier P, Terry PF, Bruinvels A, Huriez A: Market access challenges in the EU for high medical value diagnostic tests. Pers Med 2011; 8: 137-14812.
19. Velasco Garrido M, Børlum Kristensen F, Palmhøj Nielsen C, Busse R: Health Technology Assessment and Health Policy-Making in Europe. Current Status, Challenges and Potential. Brussels, European Observatory on Health Systems and Policies, 2008.
20. Institute of Medicine: Conflict of Interest in Medical Research, Education, and Practice. Washington, National Academies Press, 2009.
21. Kwon S: Positive Listing of Pharmaceuticals. Health Policy Monitor, 2007. http://www. hpm.org/survey/kr/a9/2.
22. European Commission: European Workshop on Genetic Testing Offer in Europe, EU Scientific and Policy Report by the Joint Research Centre of the European Commission, Report EUR 25684 EN. Luxembourg, Publications Office of the European Union, 2013.
23. Patrinos GP, Baker DJ, Al-Mulla F, Vasiliou V, Cooper DN: Genetic tests obtainable through pharmacies: the good, the bad and the ugly. Hum Genomics 2013; 7: 17.
24. Pavlidis C, Lanara Z, Balasopoulou A, Nebel JC, Katsila T, Patrinos GP: Meta-analysis of nutrigenomic biomarkers denotes lack of association with dietary intake and nutrient-related pathologies. OMICS 2015; 19: 512-520.
25. Pavlidis C, Patrinos GP, Katsila T: Nutrigenomics: a controversy. Appl Transl Genomics 2015; 4: 50-53.
26. European Commission: Guidelines on a Medical Device Vigilance System, E.U. DG Health and Consumers (SANCO) Directorate B-Consumer Affairs Unit B2-Health Technology and Cosmetics, MEDDEV 2.12-1 rev 8. Luxembourg, Publications Office of the European Union, 2013.
27. Evans JP, Watson MS: Genetic testing and FDA regulation: overregulation threatens the emergence of genomic medicine. JAMA 2015; 313: 669-670.
28. Council of Europe: Recommendation CM/Rec(2010)11 of the Committee of Ministers to member states on the impact of genetics on the organisation of health care services and training of health professionals, adopted by the Committee of Ministers on 29 September 2010 at the 1094th meeting of the Ministers' Deputies. Strasbourg, Council of Europe, Committee of Ministers, 2010.
29. Dierking A, Schmidtke J, Matthijs G, Cassiman J-J: The EuroGentest Clinical Utility Gene Cards continued. Eur J Hum Genet 2013; 21: 1.
30. European Commission: Recommendation on Cross Border Genetic Testing of Rare Diseases in the European Union. Brussels, EC Commission Expert Group on Rare Diseases, 2015.
31. Kierkegaard P: E-prescription across Europe. Health Technol 2013; 3: 205-219.
32. Personalized Medicine Coalition (PMC): The Adverse Impact of the US Reimbursement System on the Development and Adoption of Personalized Medicine Diagnostics, Issue Brief. Washington, Personalized Medicine Coalition, 2010.
33. Personalized Medicine Coalition (PMC): The Future of Coverage and Payment for Personalized Medicine Diagnostics. Washington, Personalized Medicine Coalition, 2014.
34. Berwouts S, Fanning K, Morris MA, Barton DE, Dequeker E: Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. Eur J Hum Genet 2012; 20: 1118-1126.
35. Berwouts S, Morris MA, Dequeker E: Approaches to quality management and accreditation in a genetic testing laboratory. Eur J Hum Genet 2010; 18(suppl 1):S1-S19.
36. The European Personalized Medicine Association: Personalised Medicine in Europe-Enhancing Patient Access to Pharmaceutical Drug-Diagnostic Companion Products, Patient Access Study. Berlin, Brüggenjürgen Institute for Social Medicine, Epidemiology, and Health Economics, Charité-Universitätsmedizin, 2014.
37. Kampourakis K, Vayena E, Mitropoulou C, Borg J, van Schaik RH, Cooper DN, Patrinos GP: Key challenges for next generation pharmacogenomics. EMBO Rep 2014; 15: 472-476.
38. Reydon TA, Kampourakis K, Patrinos GP: Genetics, genomics and society: the responsibilities of scientists for science communication and education. Pers Med 2012; 9: 633-643.
39. Snyder SR, Mitropoulou C, Patrinos GP, Williams MS: Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity. Public Health Genomics 2014; 17: 256-264.
40. Coulter A, Jenkinson C: European patients' views on the responsiveness of health systems and healthcare providers. Eur J Public Health 2005; 15: 355-360.
41. Crews KR, Hicks JK, Pui C-H, Relling MV, Evans WE: Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012; 92: 467-475.
42. Mai Y, Mitropoulou C, Papadopoulou XE, Vozikis A, Cooper DN, van Schaik RH, Patrinos GP: Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Pers Med 2014; 11: 15-26.
43. National Academies of Sciences, Engineering, and Medicine: Applying an Implementation Science Approach to Genomic Medicine: Workshop Summary. Washington, National Academies Press, 2016.